NXGL Stock Overview
Manufactures and sells high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
NEXGEL, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.08 |
| 52 Week High | US$3.14 |
| 52 Week Low | US$1.46 |
| Beta | 0.79 |
| 1 Month Change | -6.31% |
| 3 Month Change | -25.98% |
| 1 Year Change | -14.05% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -40.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| NXGL | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -11.5% | -0.8% | -0.6% |
| 1Y | -14.0% | 1.9% | 22.5% |
Return vs Industry: NXGL underperformed the US Medical Equipment industry which returned 2.1% over the past year.
Return vs Market: NXGL underperformed the US Market which returned 22.2% over the past year.
Price Volatility
| NXGL volatility | |
|---|---|
| NXGL Average Weekly Movement | 9.9% |
| Medical Equipment Industry Average Movement | 7.8% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: NXGL's share price has been volatile over the past 3 months.
Volatility Over Time: NXGL's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 19 | Adam Levy | nexgel.com |
NEXGEL, Inc. manufactures and sells high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments, Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications under the MedaGel brand; and beauty and cosmetic solutions, such as wrinkle and skin cream applications under the LumaGel Beauty brand name.
NEXGEL, Inc. Fundamentals Summary
| NXGL fundamental statistics | |
|---|---|
| Market cap | US$12.95m |
| Earnings (TTM) | -US$3.20m |
| Revenue (TTM) | US$4.74m |
2.7x
P/S Ratio-4.1x
P/E RatioIs NXGL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NXGL income statement (TTM) | |
|---|---|
| Revenue | US$4.74m |
| Cost of Revenue | US$3.78m |
| Gross Profit | US$953.00k |
| Other Expenses | US$4.15m |
| Earnings | -US$3.20m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.51 |
| Gross Margin | 20.13% |
| Net Profit Margin | -67.50% |
| Debt/Equity Ratio | 14.4% |
How did NXGL perform over the long term?
See historical performance and comparison